Livostin

   
Google
 
Web NewDrugInformation.com

Livostin


Drug - Livostin
The trade name of the product as shown on the labeling.

Dosage - SUSPENSION/DROPS; OPHTHALMIC
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Levocabastine Hydrochloride
Multiple ingredients are in alphabetical order.

Strength - EQ 0.05% BASE
The potency of the active ingredient(s), Levocabastine Hydrochloride. May repeat for multiple part products.

Applicant - NOVARTIS
The firm name holding legal responsibility for Livostin. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 020219
The FDA assigned number to Livostin. Format is nnnnnn.

Product Number - 001
The FDA assigned number to identify Livostin. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Nov 10, 1993
The date Livostin was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - Yes
The pioneer or innovator of Livostin. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - RX
The group or category of approved drugs Livostin is in. Format is RX, OTC, DISCN.

Applicant Full Name - Novartis Pharmaceuticals Corp
The full name of the firm holding legal responsibility for the new application of Livostin.

Livostin